Clinical Trial: Efficacy and Safety of Chemotherapy Combined with Aparlimtoriselizumab Induction Followed by Definitive Chemoradiotherapy for Unresectable Locally Advanced Esophageal Cancer (China)

China, Sept. 24 -- The Chinese Clinical Trial Registry (ChiCTR) received information related to the study titled 'Efficacy and Safety of Chemotherapy Combined with Aparlimtoriselizumab Induction Followed by Definitive Chemoradiotherapy for Unresectable Locally Advanced Esophageal Cancer'. The following are the other relevant details related to the trial:

Registration Number: ChiCTR2600133275

Registration Time: 2026/09/23

Type: Interventional study

Primary Sponsor: Qilu Hospital of Shandong University

To know more, click on https://www.chictr.org.cn/showprojEN.html?proj=339431

Published by HT Digital Content Services with permission from Health Daily Digest....